These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16317268)

  • 1. Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
    Giuliani F; Molica S; Maiello E; Battaglia C; Gebbia V; Di Bisceglie M; Vinciarelli G; Gebbia N; Colucci G;
    Am J Clin Oncol; 2005 Dec; 28(6):581-5. PubMed ID: 16317268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer.
    Chiesa MD; Buti S; Tomasello G; Negri F; Buononato M; Brunelli A; Lazzarelli S; Brighenti M; Donati G; Passalacqua R
    Tumori; 2007; 93(3):244-7. PubMed ID: 17679458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irinotecan and mitomycin C in 5-fluorouracil-refractory colorectal cancer patients. A phase I/II study of the Southern Italy Cooperative Oncology Group.
    Comella P; Biglietto M; Casaretti R; De Lucia L; Avallone A; Maiorino L; Di Lullo L; De Cataldis G; Rivellini F; Comella G
    Oncology; 2001; 60(2):127-33. PubMed ID: 11244327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Bamias A; Papamichael D; Syrigos K; Pavlidis N
    J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
    Yamao T; Shirao K; Matsumura Y; Muro K; Yamada Y; Goto M; Chin K; Shimada Y
    Ann Oncol; 2001 Dec; 12(12):1729-35. PubMed ID: 11843251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.
    Reni M; Panucci MG; Passoni P; Bonetto E; Nicoletti R; Ronzoni M; Zerbi A; Staudacher C; Di Carlo V; Villa E
    Cancer Invest; 2004; 22(5):688-96. PubMed ID: 15581049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
    Hamaguchi T; Shirao K; Ohtsu A; Hyodo I; Arai Y; Takiuchi H; Fujii H; Yoshida M; Saito H; Denda T; Koizumi W; Iwase H; Boku N;
    Gastric Cancer; 2011 Aug; 14(3):226-33. PubMed ID: 21503598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
    Yamao T; Ohta K; Ohyama S; Ishihara S; Chin K; Maruyama M; Takahashi T; Nakajima T
    Jpn J Clin Oncol; 2004 May; 34(5):255-61. PubMed ID: 15231860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
    Boku N; Ohtsu A; Shimada Y; Shirao K; Seki S; Saito H; Sakata Y; Hyodo I
    J Clin Oncol; 1999 Jan; 17(1):319-23. PubMed ID: 10458249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    Baek JH; Kim JG; Jeon SB; Chae YS; Kim DH; Sohn SK; Lee KB; Choi YJ; Shin HJ; Chung JS; Cho GJ; Jung HY; Yu W
    Br J Cancer; 2006 May; 94(10):1407-11. PubMed ID: 16641916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
    Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
    Yilmaz U; Oztop I; Alacacioglu A; Yaren A; Tarhan O; Somali I
    Chemotherapy; 2006; 52(5):264-70. PubMed ID: 16873996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    Stathopoulos GP; Rigatos SK; Stathopoulos JG; Xynotroulas JP; Dimou E
    Am J Clin Oncol; 2005 Dec; 28(6):565-9. PubMed ID: 16317265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Di Bartolomeo M; Buzzoni R; Mariani L; Ferrario E; Katia D; Gevorgyan A; Zilembo N; Bordonaro R; Bochicchio AM; Massidda B; Ardizzoia A; Marini G; Aitini E; Schieppati G; Comella G; Pinotti G; Palazzo S; Cicero G; Bajetta E; ; Villa E; Fagnani D; Reguzzoni G; Agostana B; Oliani C; Kildani B; Duro M; Botta M; Mozzana R; Mantovani G
    Oncology; 2006; 71(5-6):341-6. PubMed ID: 17855795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
    Lustberg MB; Bekaii-Saab T; Young D; Otterson G; Burak W; Abbas A; McCracken-Bussa B; Lustberg ME; Villalona-Calero MA
    J Thorac Oncol; 2010 May; 5(5):713-8. PubMed ID: 20354452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhao WY; Chen DY; Qi Q
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):295-8. PubMed ID: 21575503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
    Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
    Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
    Ueda S; Hironaka S; Boku N; Fukutomi A; Yoshino T; Onozawa Y
    Gastric Cancer; 2006; 9(3):203-7. PubMed ID: 16952039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
    Park SH; Choi EY; Bang SM; Cho EK; Lee JH; Shin DB; Ki Lee W; Chung M
    Anticancer Drugs; 2005 Jul; 16(6):621-5. PubMed ID: 15930889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.